Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24

Core Insights - Monopar Therapeutics Inc. has announced that its abstract on "Evaluation of Anti-uPAR Antibody as a Radiopharmaceutical for Imaging and Treatment of Solid Tumors" has been accepted as a "Top-Rated Oral Presentation" at the EANM 2024 Annual Congress [1][2] - The recognition highlights the potential of Monopar's uPAR-targeted therapy and the growing interest in uPAR as a target for radiopharmaceutical treatments [2] Company Overview - Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative cancer treatments, including the Phase 1 MNPR-101-Zr for imaging advanced cancers and the late preclinical-stage MNPR-101 radio-immuno-therapeutic (RIT) for treating advanced cancers [7] - The MNPR-101-RIT program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), such as triple-negative breast, colorectal, and pancreatic cancers [5] Clinical Trials - Monopar has initiated its first-in-human Phase 1 imaging and dosimetry clinical trial for MNPR-101-Zr in advanced cancer patients, with further details available on ClinicalTrials.gov [6]